MDW blood test to predict complications and survival after hip fracture

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll about 100 patients aged 65 and older admitted with low-energy hip fractures at the General Hospital of Attica KAT in Kifissia. MDW, measured as part of a routine complete blood count, will be collected at hospital admission, after surgery, and at additional timepoints during the hospital stay alongside other inflammatory biomarkers. Researchers will compare MDW values to postoperative outcomes including infections, sepsis, other complications, length of stay, and mortality to see if higher MDW predicts worse outcomes. Statistical models will adjust for clinical factors to determine whether MDW adds prognostic value beyond standard tests.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥65 years
* Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture)
* Admission to General Hospital of Attica KAT
* Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers

Exclusion Criteria:

* Age \<65 years
* High-energy trauma-related hip fractures
* Pathological fractures

Where it's running

• Laboratory for Research of the Musculoskeletal System
  Kifissia, Attica, Greece Recruiting

Study contacts

• Study coordinator: Efstathios Chronopoulos
• Email: stathi24@yahoo.gr
• Phone: 00306944837793

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Multicenter group study of sepsis and ARDS in China

  This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.

  Recruiting at 24 sites Shanghai Zhongshan Hospital · Xiamen, Fujian and 23 other locations · NCT07863908

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.